Néant Nadège, Gattacceca Florence, Lê Minh Patrick, Yazdanpanah Yazdan, Dhiver Catherine, Bregigeon Sylvie, Mokhtari Saadia, Peytavin Gilles, Tamalet Catherine, Descamps Diane, Lacarelle Bruno, Solas Caroline
INSERM U911-CRO2 SMARTc, Aix-Marseille University, 27 Boulevard Jean Moulin, 13005, Marseille, France.
APHP, Hôpital Bichat-Claude Bernard, Laboratoire de Pharmaco-Toxicologie, IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité and INSERM, 75018, Paris, France.
Eur J Clin Pharmacol. 2018 Apr;74(4):473-481. doi: 10.1007/s00228-017-2405-1. Epub 2018 Jan 26.
Rilpivirine, prescribed for the treatment of HIV infection, presents an important inter-individual pharmacokinetic variability. We aimed to determine population pharmacokinetic parameters of rilpivirine in adult HIV-infected patients and quantify their inter-individual variability.
We conducted a multicenter, retrospective, and observational study in patients treated with the once-daily rilpivirine/tenofovir disoproxil fumarate/emtricitabine regimen. As part of routine therapeutic drug monitoring, rilpivirine concentrations were measured by UPLC-MS/MS. Population pharmacokinetic analysis was performed using NONMEM software. Once the compartmental and random effects models were selected, covariates were tested to explain the inter-individual variability in pharmacokinetic parameters. The final model qualification was performed by both statistical and graphical methods.
We included 379 patients, resulting in the analysis of 779 rilpivirine plasma concentrations. Of the observed trough individual plasma concentrations, 24.4% were below the 50 ng/ml minimal effective concentration. A one-compartment model with first-order absorption best described the data. The estimated fixed effect for plasma apparent clearance and distribution volume were 9 L/h and 321 L, respectively, resulting in a half-life of 25.2 h. The common inter-individual variability for both parameters was 34.1% at both the first and the second occasions. The inter-individual variability of clearance was 30.3%.
Our results showed a terminal half-life lower than reported and a high proportion of patients with suboptimal rilpivirine concentrations, which highlights the interest of using therapeutic drug monitoring in clinical practice. The population analysis performed with data from "real-life" conditions resulted in reliable post hoc estimates of pharmacokinetic parameters, suitable for individualization of dosing regimen.
用于治疗HIV感染的利匹韦林存在个体间重要的药代动力学变异性。我们旨在确定成年HIV感染患者中利匹韦林的群体药代动力学参数,并量化其个体间变异性。
我们对接受每日一次利匹韦林/替诺福韦酯富马酸盐/恩曲他滨治疗方案的患者进行了一项多中心、回顾性观察研究。作为常规治疗药物监测的一部分,采用超高效液相色谱-串联质谱法测定利匹韦林浓度。使用NONMEM软件进行群体药代动力学分析。一旦选择了房室和随机效应模型,就对协变量进行测试,以解释药代动力学参数的个体间变异性。最终模型验证通过统计和图形方法进行。
我们纳入了379例患者,共分析了779个利匹韦林血浆浓度。在观察到的谷值个体血浆浓度中,24.4%低于50 ng/ml的最低有效浓度。具有一级吸收的单室模型最能描述数据。血浆表观清除率和分布容积的估计固定效应分别为9 L/h和321 L,半衰期为25.2 h。在第一次和第二次测量时,这两个参数的个体间常见变异性均为34.1%。清除率的个体间变异性为30.3%。
我们研究结果显示,终末半衰期低于报道值,且有很大比例患者的利匹韦林浓度未达最佳水平,这凸显了在临床实践中使用治疗药物监测的意义。基于“现实生活”条件下的数据进行的群体分析得出了可靠的药代动力学参数事后估计值,适用于给药方案的个体化。